Pfizer to supply 40M COVID-19 shots for poor countries

[Image]( EMAIL}/redirect FRIDAY, JANUARY 22, 2021 | LINDA A. JOHNSON, AP MEDICAL WRITER Pfizer on Friday committed to supply up to 40 million doses of its COVID-19 vaccine this year to a World Health Organization-backed effort to get affordable shots to poor and middle-income countries. The deal is a boost to the global program known as COVAX, as wealthy nations have snapped up most of the millions of coming shots. The commitment, announced at a virtual press conference held by the Geneva-based WHO, is seen as important because Pfizer and its partner BioNTech last month won the first vaccine emergency authorizations from WHO and the U.S. Food and Drug Administration. Earlier this week, WHO Director-General Tedros Adhanom Ghebreyesus criticized drugmakers for seeking profits from the pandemic and mostly supplying wealthy countries. Pfizer's 40 million doses — for a vaccine requiring two doses — are a tiny sliver of what's needed for COVAX, which aims to vaccinate billions of people in 92 low- and middle-income countries. During Friday’s news conference, Tedros said Pfizer’s commitment and about 150 million doses of the vaccine developed by AstraZeneca and Oxford University could enable COVAX to begin delivering doses in February, pending finalization of a supply agreement with Pfizer and emergency use approval for AstraZeneca’s vaccine. He said the global program is on track to deliver by year’s end 2 billion doses of vaccines previously pledged by AstraZeneca and other vaccine producers. New York-based Pfizer Inc. had not previously committed to providing its COVID-19 vaccine to poor countries without making a profit during the pandemic, as a couple rivals have. However, Pfizer and Germany’s BioNTech said they would provide their vaccine to COVAX at an undisclosed “not-for-profit price.” The companies still must execute a supply agreement covering distribution, but the doses are to be delivered throughout 2021, starting in February. EMAIL}/redirect EMAIL}/redirect “Today, we are proud to have this opportunity to provide doses that will support COVAX efforts toward vaccinating healthcare workers at high risk of exposure in developing countries and other vulnerable … populations,” Pfizer Chief Executive Officer Albert Bourla said. Dr. Seth Berkley, CEO of GAVI, the Vaccine Alliance, which is leading procurement and delivery of vaccines for COVAX, called the deal “a major step forward for equitable access to vaccines.” Pfizer and BioNTech said they would also help health systems handle the vaccine, which requires ultracold storage. EMAIL}/redirect EMAIL}/redirect Many public health officials have expressed skepticism that the Pfizer vaccine could be successfully kept so cold across the globe. Pfizer has been shipping the shots in special containers with dry ice, but even in the U.S. some doses have been thrown out because they weren't kept at the proper temperature. Pfizer has said it’s been ramping up production and expects to be able to make 2 billion doses in 2021, up from its earlier forecast of 1.3 billion doses. That long-term goal comes with a short-term cost: The company is slowing production at its Belgium factory while it makes changes needed to boost production. ___ Follow Linda A. Johnson on Twitter: @LindaJ_onPharma EMAIL}/redirect EMAIL}/redirect © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as are commendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has not been compensated for this specific email, we do have advertisements in this email that we get paid if you click one of the ads (we have not investigated any of the advertisements). Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( [Change subscriber options](